Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04242004

Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients

Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients: A Randomized, Double-blind, Placebo-controlled Study

Sponsor: Fudan University

Conditions Neurocognitive Impairment

Interventions Docosahexaenoic acid (DHA) capsules Soy oil capsules

Updated 5 times since 2020 Last updated: Jan 23, 2020 Started: Oct 30, 2019 Primary completion: Mar 1, 2020 Completion: May 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Neurocognitive Impairment, this trial is ongoing. The trial is conducted by Fudan University and has accumulated 5 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2022 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Active Not Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
Feb 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1_PHASE2

First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China